Vaxcyte Inc.

Vaxcyte Inc.

World Rank (Jan-05-2024)
2,495
Market Cap (Jan-05-2024)
6.122 Billion USD
World Rank (Jul-30-2023)
3,324
Market Cap (Jul-30-2023)
4.376 Billion USD
World Rank (Jan-07-2022)
8,241
Market Cap (Jan-07-2022)
1.256 Billion USD
World Rank (Jan-01-2021)
6,750
Market Cap (Jan-01-2021)
1.354 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
PCVX
Market Cap (Mar-08-2026)
8.53
Employee Count
158
Employee Count as of Date
As on 2022
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-207 Million USD
Annual Net Income in USD
-223 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
1,006 Million USD
Total Liabilities in USD
53 Million USD
Total Equity in USD
953 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
VAXCYTE, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile

Vaxcyte is a Biotechnology company developing potentially superior and novel vaccines designed to prevent or treat the most common and deadly infectious diseases worldwide. It is having 43 employees as on 2019. The headquarters is in USA.

Annual Results Summary

VAXCYTE, INC - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-20220 -207 (Loss)-223 (Loss)
Dec-20210-102 (Loss)-100 (Loss)
Dec-20200-87 (Loss)-89 (Loss)
Dec-20190-53 (Loss)-53 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,006 Million USD.

Total Liabilities as on Dec-2022 was 52 Million USD.

Total Equity as on Dec-2022 was 953 Million USD.

IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share